Revance Therapeutics (RVNC) Now Covered by Guggenheim

Equities research analysts at Guggenheim assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a note issued to investors on Tuesday. The firm set a “buy” rating on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on RVNC. BidaskClub lowered shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Cantor Fitzgerald set a $50.00 price target on shares of Revance Therapeutics and gave the company a “buy” rating in a research note on Tuesday. Zacks Investment Research downgraded shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. ValuEngine downgraded shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday. Finally, Barclays began coverage on shares of Revance Therapeutics in a research note on Monday, November 27th. They issued an “overweight” rating and a $31.00 price target for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $38.14.

Revance Therapeutics (NASDAQ:RVNC) traded up $8.75 during mid-day trading on Tuesday, reaching $34.75. 8,133,983 shares of the company traded hands, compared to its average volume of 218,294. Revance Therapeutics has a 1-year low of $15.85 and a 1-year high of $37.20.

Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by ($0.06). The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. Revance Therapeutics’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.64) EPS. equities analysts expect that Revance Therapeutics will post -3.73 EPS for the current year.

In other Revance Therapeutics news, CEO L Daniel Browne sold 7,600 shares of Revance Therapeutics stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $23.58, for a total value of $179,208.00. Following the completion of the sale, the chief executive officer now directly owns 148,450 shares of the company’s stock, valued at $3,500,451. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Mark J. Foley purchased 20,000 shares of the firm’s stock in a transaction on Tuesday, November 7th. The stock was bought at an average cost of $26.96 per share, with a total value of $539,200.00. Following the completion of the purchase, the director now owns 6,000 shares of the company’s stock, valued at approximately $161,760. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 44,026 shares of company stock valued at $1,135,234. Insiders own 18.86% of the company’s stock.

Large investors have recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of Revance Therapeutics during the third quarter worth about $144,000. Bank of America Corp DE increased its position in shares of Revance Therapeutics by 29.5% during the first quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 1,651 shares in the last quarter. Legal & General Group Plc increased its position in shares of Revance Therapeutics by 8.1% during the second quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock worth $152,000 after acquiring an additional 438 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of Revance Therapeutics during the second quarter worth about $231,000. Finally, Voya Investment Management LLC bought a new stake in shares of Revance Therapeutics during the second quarter worth about $274,000. 88.70% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Revance Therapeutics (RVNC) Now Covered by Guggenheim” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.com-unik.info/2017/12/05/revance-therapeutics-rvnc-now-covered-by-guggenheim.html.

About Revance Therapeutics

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

What are top analysts saying about Revance Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Revance Therapeutics Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit